Cargando…
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials
γδ T lymphocytes represent an emerging class of cellular immunotherapy with preclinical promise to treat cancer, notably neuroblastoma. The innate-like immune cell subset demonstrates inherent cytoxicity toward tumor cells independent of MHC recognition, enabling allogeneic administration of healthy...
Autores principales: | Jonus, Hunter C., Burnham, Rebecca E., Ho, Andrew, Pilgrim, Adeiye A., Shim, Jenny, Doering, Christopher B., Spencer, H. Trent, Goldsmith, Kelly C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966991/ https://www.ncbi.nlm.nih.gov/pubmed/35371623 http://dx.doi.org/10.1080/2162402X.2022.2057012 |
Ejemplares similares
-
Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy
por: Burnham, Rebecca E., et al.
Publicado: (2020) -
The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1
por: Pilgrim, Adeiye A., et al.
Publicado: (2023) -
Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
por: Zoine, Jaquelyn T., et al.
Publicado: (2019) -
Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma
por: Lee, Jasmine Y., et al.
Publicado: (2023) -
In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study
por: Pressey, Joseph G., et al.
Publicado: (2016)